These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 35156644)

  • 1. Assessment of Voice Outcomes Post Chemo-Radiotherapy in Non-Laryngeal Head & Neck Cancers Using Electroglottography and Voice Symptom Scale (VoiSS) Questionnaire.
    Radhakrishna N; Yamini BK; Sadashiv Kadam A; Shivashankar N; Vishwanathan C; Javarappa R
    Gulf J Oncolog; 2022 Jan; 1(38):47-52. PubMed ID: 35156644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acoustic analysis of voice in nonlaryngeal head and neck cancer patients post chemoradiotherapy.
    Radhakrishna N; Yamini BK; Kadam AS; Shivashankar N; Vishwanathan C; Javarappa R
    J Cancer Res Ther; 2017; 13(1):113-117. PubMed ID: 28508843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective clinical study on long-term swallowing function and voice quality in advanced head and neck cancer patients treated with concurrent chemoradiotherapy and preventive swallowing exercises.
    Kraaijenga SA; van der Molen L; Jacobi I; Hamming-Vrieze O; Hilgers FJ; van den Brekel MW
    Eur Arch Otorhinolaryngol; 2015 Nov; 272(11):3521-31. PubMed ID: 25381096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extreme long-term voice outcomes after concurrent chemoradiotherapy for advanced non-laryngeal head and neck cancer: Eight-year post-treatment analysis.
    Davies-Husband C; Murphy J; Kelly C; Drinnan M; Paleri V
    Clin Otolaryngol; 2018 Dec; 43(6):1494-1499. PubMed ID: 30066393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre- and posttreatment voice and speech outcomes in patients with advanced head and neck cancer treated with chemoradiotherapy: expert listeners' and patient's perception.
    van der Molen L; van Rossum MA; Jacobi I; van Son RJ; Smeele LE; Rasch CR; Hilgers FJ
    J Voice; 2012 Sep; 26(5):664.e25-33. PubMed ID: 22209059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of symptom burden during radiotherapy or concurrent chemoradiotherapy for head and neck cancer: a prospective analysis using the University of Texas MD Anderson Cancer Center Symptom Inventory-Head and Neck Module.
    Rosenthal DI; Mendoza TR; Fuller CD; Hutcheson KA; Wang XS; Hanna EY; Lu C; Garden AS; Morrison WH; Cleeland CS; Gunn GB
    Cancer; 2014 Jul; 120(13):1975-84. PubMed ID: 24711162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of life and voice following endoscopic resection or radiotherapy for early glottic cancer.
    Loughran S; Calder N; MacGregor FB; Carding P; MacKenzie K
    Clin Otolaryngol; 2005 Feb; 30(1):42-7. PubMed ID: 15748189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Voice outcomes after concurrent chemoradiotherapy for advanced nonlaryngeal head and neck cancer: a prospective study.
    Paleri V; Carding P; Chatterjee S; Kelly C; Wilson JA; Welch A; Drinnan M
    Head Neck; 2012 Dec; 34(12):1747-52. PubMed ID: 22319013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment and prevalence of concomitant chemo-radiotherapy-induced oral mucositis in patients with oral squamous cell carcinoma.
    Minhas S; Sajjad A; Chaudhry RM; Zahid H; Shahid A; Kashif M
    Turk J Med Sci; 2021 Apr; 51(2):675-684. PubMed ID: 33155791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Electronic patient-reported outcomes and toxicities during radiotherapy for head-and-neck cancer.
    Niska JR; Halyard MY; Tan AD; Atherton PJ; Patel SH; Sloan JA
    Qual Life Res; 2017 Jul; 26(7):1721-1731. PubMed ID: 28247313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Locally advanced squamous cell carcinoma of the head and neck: A systematic review and Bayesian network meta-analysis of the currently available treatment options.
    Iocca O; Farcomeni A; Di Rocco A; Di Maio P; Golusinski P; Pardiñas López S; Savo A; Pellini R; Spriano G
    Oral Oncol; 2018 May; 80():40-51. PubMed ID: 29706187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVID-19 pandemic: The Princess Margaret experience and proposal.
    Huang SH; O'Sullivan B; Su J; Ringash J; Bratman SV; Kim J; Hosni A; Bayley A; Cho J; Giuliani M; Hope A; Spreafico A; Hansen AR; Siu LL; Gilbert R; Irish JC; Goldstein D; de Almeida J; Tong L; Xu W; Waldron J
    Cancer; 2020 Aug; 126(15):3426-3437. PubMed ID: 32478895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Voice and swallowing outcomes of an organ-preservation trial for advanced laryngeal cancer.
    Fung K; Lyden TH; Lee J; Urba SG; Worden F; Eisbruch A; Tsien C; Bradford CR; Chepeha DB; Hogikyan ND; Prince ME; Teknos TN; Wolf GT
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1395-9. PubMed ID: 16087298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of voice, speech, and related quality of life in advanced head and neck cancer patients 10-years+ after chemoradiotherapy.
    Kraaijenga SA; Oskam IM; van Son RJ; Hamming-Vrieze O; Hilgers FJ; van den Brekel MW; van der Molen L
    Oral Oncol; 2016 Apr; 55():24-30. PubMed ID: 26874554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxicities affecting quality of life after chemo-IMRT of oropharyngeal cancer: prospective study of patient-reported, observer-rated, and objective outcomes.
    Hunter KU; Schipper M; Feng FY; Lyden T; Haxer M; Murdoch-Kinch CA; Cornwall B; Lee CS; Chepeha DB; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):935-40. PubMed ID: 23040224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Maitake D-fraction in advanced laryngeal and pharyngeal cancers during concurrent chemoradiotherapy: A randomized clinical trial.
    Hu Q; Xie B
    Acta Biochim Pol; 2022 Sep; 69(3):625-632. PubMed ID: 36070433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective randomized trial to compare accelerated (six fractions a week) radiotherapy against concurrent chemoradiotherapy (using conventional fractionation) in locally advanced head and neck cancers.
    Gupta M; Mahajan R; Kaushal V; Seem RK; Gupta M; Bhattacharyya T
    J Cancer Res Ther; 2015; 11(4):723-9. PubMed ID: 26881508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Global quality of life during the acute toxicity phase of multimodality treatment for patients with head and neck cancer: can we identify patients most at risk of profound quality of life decline?
    Tribius S; Reemts E; Prosch C; Raguse M; Petersen C; Kruell A; Singer S; Bergelt C
    Oral Oncol; 2012 Sep; 48(9):898-904. PubMed ID: 22502815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of vocal rehabilitation after chemoradiation for non-laryngeal head and neck cancers.
    Sreenivas A; Sreedharan S; Narayan M; Balasubramanium RK; Saxena PP; Banerjee S; Dosamane D; Shenoy V; Kamath MP
    Acta Otorhinolaryngol Ital; 2021 Apr; 41(2):131-141. PubMed ID: 34028457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-reported voice and speech outcomes after whole-neck intensity modulated radiation therapy and chemotherapy for oropharyngeal cancer: prospective longitudinal study.
    Vainshtein JM; Griffith KA; Feng FY; Vineberg KA; Chepeha DB; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2014 Aug; 89(5):973-980. PubMed ID: 24803039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.